KomalJhaveriMDFACP

Breast Cancer, Hematologic Oncology

Assistant Attending

Overview of Dr. Jhaveri

Dr. Komal Jhaveri is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from KJ Somaiya Medical College and has been in practice 16 years. Dr. Jhaveri accepts several types of health insurance, listed below. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Gujarati, Hindi, Marathi, and Urdu. She has more than 100 publications and over 500 citings.

Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Book by Phone+1(213) 568-0205

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
KJ Somaiya Medical CollegeClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2009 - 2026
NJ State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Conquer Cancer Foundation Young Investigator Award ASCO

Clinical Trials

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
Completed
Phase 1, Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Exemestane and Cyclophosphamide for Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression Start of enrollment: 2017 May 18
Terminated
Phase 1
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer Start of enrollment: 2017 Aug 18
Active, not recruiting
Phase 1
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer Start of enrollment: 2017 Nov 10
Completed
Phase 1, Phase 2
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) Start of enrollment: 2015 Aug 12
Active, not recruiting
Phase 2
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Start of enrollment: 2021 Sep 09
Withdrawn
Phase 1
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Start of enrollment: 2021 Oct 08
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial ca...
Kan Yonemori, Valentina Boni, Kim Gun Min, Tarek M Meniawy, Janine Lombard
Gynecologic Oncology. 2024-12-01
1 citations
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advance...
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella
Journal of Clinical Oncology. 2024-11-20

Lectures

Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Res...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast CancerDecember 22nd, 2024
Imlunestrant Improves PFS Among Patients with ESR1-Mutated ER-Positive, HER2-Negative ABC and in Combination with Abemaciclib Regardless of ESR1 Mutation StatusDecember 17th, 2024
Lilly’s Imlunestrant Improves Progression-Free Survival as Monotherapy in Patients with ER+, HER2- Advanced Breast CancerDecember 15th, 2024
Join now to see all

Professional Memberships

Amersican Soceity of Clinical Oncology
Member

Other Languages

Gujarati, Hindi, Marathi, Urdu

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment